This Week published in the New England Journal of Medicine, the study shows, such a such a careful and critical observation in early clinical trials of new therapies, new insight into the causes of self - ' 'simplest 'single gene disorders. 'These lessons are, for the future be extensively explored for the future, and should help us understand how to better fit our treatment to the needs of patients approaching adjusted, 'said study author R.
A lesson from this study suggests that a careful eye could on the immune response profiles of patients contribute to the success not only to improve gene therapy, but also other therapies to restore dystrophin activity from. Steven Gray, PhD;; Chengwin Li, PhD, - The research was supported in part by the Muscular Dystrophy Association and UNC startup biotech company Asklepios biopharmaceutical Inc. Study co-authors from UNC include Dawn Bowles, PhD funding and Xiao Xiao.Performed of the University of Maryland School of Medicine include Diana Miller and Ricardo Feldman, 10 did. A teaching body appointment to Associate Professor in to the Department of Pathology and Laboratory Medicine at University of Kansas School of Medicine Find out more about their Research Programme.